Oncoinvent Registers Share Capital Increase Ahead of Reverse Share Split

BerGenBio ASA ( (BRRGF) ) has shared an update.

Oncoinvent ASA has completed a minor share capital increase tied to the issuance of 75 new shares to Abakus Invest AS, a technical step to facilitate a reverse share split. Following registration of the increase in the Norwegian Register of Business Enterprises, the company’s share capital now stands at NOK 223,920,600 divided into 447,841,200 shares with a nominal value of NOK 0.50, a change that streamlines the capital structure without altering the fundamental operations or clinical development trajectory of its lead cancer therapy, Radspherin®.

More about BerGenBio ASA

Oncoinvent ASA is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies for cancer. Its lead product candidate, Radspherin®, is an investigational alpha-emitting radium-224-based therapy designed to locally target micro-metastases and peritoneal carcinomatosis from ovarian and colorectal cancer following surgical tumor resection. The company operates a state-of-the-art manufacturing facility in Oslo, employs around 40 people, is listed on the Oslo Stock Exchange, and is advancing Radspherin® through an ongoing randomized Phase 2 trial in the US, UK and Europe after completing earlier-stage clinical studies with encouraging safety and efficacy data.

Average Trading Volume: 1,436,312

Current Market Cap: NOK203.1M

For an in-depth examination of BRRGF stock, go to TipRanks’ Overview page.